Home > Anti-aging Research > Deprenyl.

Deprenyl (Selegiline, Eldepryl, Emsam, etc.)

Related Topics:

• dopamine / Monoamine Oxidase (MAO) Inhibitors / antidepressants / Parkinson's Disease / depression / attention deficient hyperactive disorder

Where to purchase:

• Deprenyl at reliablerxpharmacy.com

News & Research:

• Deprenyl - extending lifespan - article by James South - "At normally used clinical dosages (10-15 mg/day), deprenyl is a selective MAO-B inhibitor, so it doesn’t prevent intestinal MAO-A from digesting dietary tyramine. (1) In addition, deprenyl has the unique ability to prevent tyramine from getting into noradrenalin-using nerve calls, and it’s only when tyramine enters noradrenalin nerve cells that control arterial blood pressure that it triggers the “cheese effect.”"
• Deprenyl- A multi-functional anti-aging drug - Ward Dean MD - "In addition to its potential as a life-extending drug, Deprenyl also appears to have a number of other beneficial effects. One of the most significant is its libido promoting/aphrodisiac effects, in both men and women. . . . Deprenyl has also been found to protect neurons from toxic substances, act as an anti-oxidant, and as an inducer of the anti-oxidant enzymes superoxide dismutase (SOD) and catalase (CAT)"
• Deprenyl - International Antiaging Systems
• Deprenyl: A Universal Anti-Aging Strategy - CERI
• The Responsible Parent's Guide to Healthy Mood-Boosters for all the Family - BLTC Research
• How to boost happiness hormones like serotonin and dopamine - CNET, 11/18/20 - "Almost everything that makes you feel "happy" is linked to one of the four happiness hormones: dopamine, serotonin, endorphin and oxytocin. Here are some ways you can boost them" - Note:  They keep claiming exercise but I've been exercising my entire life.  I think you get more bang plus anti-aging benefits by taking deprenyl.
• Selegiline transdermal system promising for social phobia - Clinical Psychiatry News, 6/26/13 - "Twenty patients participated in this 12-week, open-label, pilot study. They were treated with the selegiline transdermal system (Emsam) at a dose of 6 mg/24 hours. They demonstrated a significant mean 7.1-point drop from a baseline score of 17.6 on the avoidance component of the Liebowitz Social Anxiety Scale, as well as a 6.6-point drop on the scale’s anxiety component, a result that just missed statistical significance ... Selegiline is an MAO-A and -B inhibitor. Its transdermal administration bypasses the GI tract and liver, thereby essentially eliminating the risks of hypertensive crisis and dietary interactions with tyramine-rich foods, which have demoted the traditional oral monoamine oxidase (MAO) inhibitors in antidepressant treatment hierarchies ... In addition to the favorable results on the Liebowitz Social Anxiety Scale over the course of 12 weeks, participants also showed statistically significant improvements on the Social Life/Leisure Activities domain of the Sheehan Disability Scale, the Clinical Global Impression Severity of Illness Scale, and the Clinical Global Impression Change Scale" - Note:  Emsam is the patch form of deprenyl (also called selegiline) which has been touted for anti-aging since around the '70's.  See deprenyl at International Anti-aging Systems.
• Study Will Test Antidepressant Patch That May Help Smokers Kick The Habit - Science Daily, 1/8/07
• Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients - Doctor's Guide, 7/21/06
• Patch Approval: ‘Big Moment’ in Psychopharm: Resistant depression patients may benefit - Clinical Psychiatry News, 4/06 - "Probably 30% of people who present with depressive complaints have an MAO-inhibitor responsive condition that will not respond well or not at all to [selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, or tricyclics]"
• FDA Approves Emsam (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder - Doctor's Guide, 2/28/06 - "the U.S. Food and Drug Administration (FDA) approved Emsam® (selegiline transdermal system), the first transdermal patch for the treatment of major depressive disorder (MDD) in adults"
• FDA OKs Patch to Treat Depression - WebMD, 2/28/06 - "At its lowest strength, Emsam can be used without the dietary restrictions that are needed for all oral MAO inhibitors that are approved for treating major depression"
• FDA Panel Backs Selegiline Patch For Depression: Majority view 20-mg formulation as safe - Clinical Psychiatry News, 12/05 - "Unlike the transdermal formulation, the oral formulation does not achieve antidepressant levels in the central nervous system"
• Fast-dissolving Selegiline (Zelapar Zydis) Reduces "Off-Time" in Up to 4 Years of Follow-Up - Doctor's Guide, 10/3/05
• Parkinson's Drug May Be Safer Than Thought - WebMD, 8/12/04
• Transdermal Selegiline Can Prevent Depression Relapse - Clinical Psychiatry News Online, 11/03
• Transdermal MAO Inhibitor Patch Effective for ADHD - Clinical Psychiatry News, 6/03 - "A transdermal patch containing the selective monoamine oxidase inhibitor selegiline applied daily appeared effective and well tolerated in a pilot study of children and adolescents with attention-deficit hyperactivity disorder ... Selegiline is a specific monoamine oxidase (MAO) type B inhibitor, so it “is essentially devoid of the tyramine-cheese effect we think about with MAO [type A] inhibitors"
• Selegiline Transdermal System Shows Modest But Significant Antidepressant Effect - Doctor's Guide, 3/19/03 - "Use of a selegiline transdermal system offers modest but statistically significant antidepressant benefit in outpatients with major depressive disorder"
• Zelapar (Selegiline) Receives Approvable Letter From FDA - Doctor's Guide, 2/18/03
• Parkinson's Drug May Help Smokers Quit - WebMD, 1/24/03
• Selegiline Helps Smokers Quit - Medscape, 1/23/03 - "Its effect was about half that of buproprion but comparable to that of nicotine replacement ... selegiline doses greater than 10 mg/day are associated with increased risk of hypertensive crises"
• Selegiline Might Aid Smoking Cessation - Doctor's Guide, 9/12/02
• Transdermal MAO Inhibitor Appears Safe Without Dietary Restrictions - Clinical Psychiatry News, 9/01 - "Selegiline is a MAO-B inhibitor that has been shown to have a significant antidepressant effect at oral doses of 30-60 mg/day. But at this level, the drug also inhibits MAO-A and requires the restriction of dietary tyramine and sympathomimetic amines"
• Deprenyl May Result In AD/HD Symptom Improvements - Doctor's Guide, 10/26/99 - "Ten children (ages six to 13) with AD/HD participated in the study. These children had very severe AD/HD and presented many co-morbid problems. Placebo and deprenyl tablets (5 mg) were given twice a day for one month each ... Results showed that three tasks were significantly improved (paired-associate learning, math computation and Beery shape copying) with deprenyl treatment as determined by a two-tailed statistical test. This pilot study indicates that deprenyl may have some benefits for the task performance and classroom behavior of some children with AD/HD."
• A Good Dose of Deprenyl How Much is Too Much? - Life Extension Magazine, 8/99
• Selegiline - BLTC Research
• Youthful Brain, Youthful Body - Life Extension Magazine, 5/98
• Effect Of Long-Term Deprenyl Treatment On Age-Dependent Changes In The Rat Brain - Life Extension Magazine, 9/96
• Top Ten Life Extension Drugs - Life Extension Magazine, 9/95
• Eldepryl Shows Encouraging Results In Alzheimer's Study - Doctor's Guide, 4/24/97
• Report: Vitamin E, Parkinson's drug slow Alzheimer's disease - CNN, 4/23/97

Abstracts:

• Someone asked me about Alzheimer's. Personally, I'd be taking everything in the book to prevent or delay it. People have no idea the burden that puts on the family. An important item is selegiline. I've been taking it for decades for anti-aging.
  • Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group - J Psychiatry Neurosci. 1999 May; 24(3): 234–243 - "A total of 143 subjects completed enough of the trial to be entered in the analysis. Subjects were analyzed by 2 subgroups depending on whether they had a normal or pathologic result of the Clock Drawing Test. Analysis of variance showed significant improvement with selegiline versus placebo among those with a normal result of the Clock Drawing Test on the Mini Mental Status Examination (total score and orientation-place subscale) and among those with a pathologic result of the Clock Drawing Test of Sternberg's Memory Scanning test (for both speed and accuracy), on the Clinical Global Impressions scale as well as in terms of the dominant frequency on electroencephalograms. CONCLUSION: Selegiline has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas of the brain, which are rich in dopamine receptors. The delayed appearance of differences between selegiline and placebo supports the notion that the mechanism of action is through neuronal rescue or neuroprotection. The differential response of patients with normal and pathologic results of the Clock Drawing Test may reflect the fact that the evaluation methods' sensitivity to change depends on the severity of dementia" - See selegiline at ReliableRXPharmacy.
• Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats - Br J Pharmacol. 2018 Jul 3 - "Certain monoamine-oxidase (MAO) inhibitors have been shown to reduce body weight, although their effect on metabolic parameters have not been investigated. Here we assessed the effect of a widely used, selective MAO-B inhibitor, selegiline, on metabolic parameters in high-fat, high-sucrose diet-induced rat model of obesity ... Male Long-Evans rats were fed with control (CON) or high-fat (20%), high-sucrose (15%) diet (HFS) for 25 weeks. From week 16 groups of animals received subcutaneous injections of 0.25 mg kg-1 selegiline (CON+S and HFS+S) or vehicle (CON, HFS) once daily ,,, Selegiline decreased whole body fat, subcutaneous and visceral adiposity as measured by computer tomography and epididymal fat weight in the HFS group as compared to HFS placebo animals without influencing body weight. Oral glucose tolerance test and insulin tolerance test results showed impaired glucose homeostasis in HFS and HFS+S groups despite unchanged insulin levels in the blood plasma and pancreas. HFS induced expression of Srebp-1c, Glut1, and Mip1α in adipose tissue, which was alleviated by selegiline treatment ... These results suggest the potential benefit of selegiline to mitigate harmful effects of visceral adiposity" - See deprenyl (selegiline) at The Antiaging Store.  I've been taking 5 mg per day since Moby Dick was a minnow.
• Selegiline transdermal system: a novel treatment option for major depressive disorder - Expert Opin Pharmacother. 2009 Jul;10(10):1665-73 - "Selegiline transdermal system is safe and effective in treating major depressive disorder at the dose range of 6 - 12 mg/24 h, without the need for dietary precautions at the 6 mg/24 h dose. No cases of hypertensive crisis were reported in clinical trials, even without dietary restrictions"
• Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients - Am J Psychiatry, 11/02 - "Transdermal selegiline (20 mg applied once daily by means of a 20-cm2 patch) administered for 6 weeks was an effective and well-tolerated treatment for adult outpatients with major depression. The typical side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not observed"
• MAO inhibitors and oxidant stress in aging brain tissue - Eur Neuropsychopharmacol. 1999 Mar;9(3):247-52 - "By reducing the oxidant stress observed in aging brain, MAO inhibitors, especially deprenyl, may contribute to the control of the aging process."
• Current status of antioxidant therapy for Alzheimer's Disease - J Am Geriatr Soc. 1998 Dec;46(12):1566-72 - "High dose vitamin E, ginkgo biloba, and selegiline are three putative antioxidants that have been tested in randomized multicenter trial conditions in the US"
• The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl - Mech Ageing Dev. 1988 Dec;46(1-3):237-62
• Integrated medicine and the prevention and reversal of memory loss - Altern Ther Health Med. 1998 Nov;4(6):38-43 - "The program includes a diet consisting of 15% fat and supplementation with brain-specific nutrients such as vitamin B complex, vitamin E, ubiquinone, ginkgo biloba, and phosphatidylserine. In addition, stress-relieving meditation, mind-body and cognitive exercise, antiaging drugs like L-deprenyl citrate, as well as hormones such as dehydroepiandrosterone and pregnenolone complete the program"
• Cortisol is higher in parkinsonism and associated with gait deficit - Acta Neurol Scand. 1998 Feb;97(2):77-85 - "Selegiline was associated with a lower cortisol"
• Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors - Cancer Lett. 1998 Jan 30;123(2):177-83 - "These results suggest that the administration of deprenyl blocked the development of mammary tumors . . ."